AstraZeneca India To Sell 64-Acre Bengaluru Facility
Real Estate

AstraZeneca India To Sell 64-Acre Bengaluru Facility

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. 

According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. 

The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. 

A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

Next Story
Infrastructure Transport

Tata, Airbus to Build India’s First Private Helicopter Line

In a landmark development for India’s aerospace sector, Tata Advanced Systems Limited (TASL) and Airbus will establish the country’s first private-sector helicopter assembly line in Vemagal, Karnataka. The facility will manufacture the Airbus H125 and H125M, marking a significant milestone in India’s push for self-reliance in aviation and defence manufacturing. The new Final Assembly Line (FAL) will produce the H125, the world’s best-selling single-engine helicopter, known for its versatility and performance in extreme environments. The first ‘Made in India’ H125 is expected to ro..

Next Story
Infrastructure Urban

NeGD to Support Bharat Taxi in Building Cooperative Ride Platform

In a significant move for India’s digital and mobility transformation, the National e-Governance Division (NeGD) of the Digital India Corporation, under the Ministry of Electronics and Information Technology (MeitY), has entered into an advisory partnership with Sahakar Taxi Cooperative Limited, the company behind Bharat Taxi — a first-of-its-kind, cooperative-led national ride-hailing platform. A Memorandum of Understanding (MoU) has been signed between NeGD and Sahakar Taxi to provide strategic advisory and technical support covering key areas such as platform integration, cybersecurity..

Next Story
Technology

MeitY Hosts Pre-Summit for India–AI Impact Summit 2026

The Ministry of Electronics and Information Technology (MeitY), Government of India, hosted a series of Pre-Summit events for the upcoming India–AI Impact Summit 2026 at the India Mobile Congress (IMC) 2025 in New Delhi. These sessions mark a key milestone ahead of the main summit, scheduled for 19–20 February 2026 at Bharat Mandapam, New Delhi. Delivering the inaugural address, S. Krishnan, Secretary, MeitY, highlighted India’s innovative and frugal approach to AI development. “We have adopted innovative means by learning from others’ experiences to build projects and products that..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?